Depression in Children and Adolescents: Assessment, Treatment Evidence and Safety

Direct answer: Depression can affect children and adolescents, sometimes appearing as irritability, withdrawal or problems at school rather than only sadness. Assessment must include safety, bullying, abuse, family and developmental context. Child-specific psychological care and specialist medication decisions differ from an adult treatment plan. Confidence is high in the need for appropriate assessment and safety review, and moderate in this selected summary of clinical care pathways. A supplement substitute is not independently established here. Recommendations are not relabeled as clean, independently replicated trial results (NHS depression in children and young people).

Table of contents

• Evidence summary
• What it is
• How it works
• The evidence-based treatments
• Supplement and lifestyle evidence
• What works and what does not
• Risks and side effects
• Important interactions
• Who should avoid unsupervised treatment
• Dosage and how to take
• Animal and in-vitro evidence
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

The source roles below are deliberately different. A health-agency explanation can support definitions and a clinical guideline can describe recommended care; neither automatically clears the funding of its supporting trials. This selected review does not provide a newly pooled treatment-effect estimate.

What it is

A sustained change in enjoyment, mood, energy, sleep or participation deserves attention. The NHS describes irritability, isolation and physical complaints as possible features in young people. These are reasons for assessment, not a checklist proving depression. Physical illness, anxiety, developmental needs, substances and other mood disorders can overlap. The clinician should hear from the young person as well as caregivers, in an accessible language and format. NICE recommends an opportunity to discuss sensitive issues privately, including bullying, abuse, alcohol or drugs, self-harm and suicidal ideas. A school report is useful context but does not replace the young person’s account. (NHS depression in children and young people).

How it works

NIMH describes depression as involving genetic, biological, environmental and psychological factors. Family difficulties or adverse experiences can contribute without being a complete cause or proof that a parent is to blame. The formulation should identify continuing practical problems, including an unsafe environment, rather than asking the child to change thoughts about a genuine threat. A family history of bipolar disorder matters to assessment. There is no routine blood test that diagnoses the condition from a presumed serotonin deficiency. (NHS depression in children and young people).

The evidence-based treatments

NICE recommends care matched to age, severity and circumstances, with psychological therapies and coordinated involvement of family or carers where appropriate. Medication decisions are specific to young people; the guideline includes specialist review, clear rationale and close monitoring rather than copying adult prescribing. Antidepressants should not be presented as a casual first response to every low mood, nor ruled out categorically when a clinician finds them appropriate. NICE specifies circumstances for combined psychological and medication care in moderate or severe depression. This article provides no personal drug choice or dose. A care plan should explain who monitors progress, what changes require contact, and how school, family and clinical services communicate. Recommendation text is clinical guidance; supporting trials have not all been financially cleared for an independent comparative effect estimate. (NHS depression in children and young people; NICE depression in children and young people).

Supplement and lifestyle evidence

Regular sleep, a balanced diet, manageable activity and support can help a person participate in care. They should be adapted to health and circumstances. General wellbeing benefits do not prove that a routine treats this particular disorder or prevents recurrence. Evidence about stress in healthy volunteers cannot automatically answer a question about a diagnosed clinical condition (NIMH psychotherapies).

This guide establishes no independent supplement replacement for condition-specific assessment and treatment. The public complementary-health summary is used to identify limits and precautions, not to certify the independence of every underlying product study. A manufacturer-funded positive trial, a gift of study material, or an author’s relevant sales interest would exclude that outcome from the strict independent verdict. Unknown finances would remain unknown, rather than be called clean (NCCIH depression).

What works and what does not

Progress includes the young person’s functioning, interests, relationships and safety, rather than only a questionnaire score or better classroom compliance. Support at school can improve access while treatment proceeds. A quiet child should not be assumed to be well, and a distressed child should not be dismissed as merely difficult.

Risks and side effects

Self-harm, an overdose, suicidal intent or inability to keep the young person safe requires urgent help. Report new agitation or behavioural changes after a medication change promptly. Abuse and safeguarding concerns need the appropriate professional response.

Thoughts of suicide, a plan to act, or inability to keep yourself or another person safe need urgent help. In an immediate danger, contact local emergency services; in the United States, 988 provides crisis support and 911 is for life-threatening emergencies. These numbers are jurisdiction-specific. Tell a trusted person and obtain help rather than relying on an article or supplement. If someone is at immediate risk, do not leave them alone while arranging safe assistance (NIMH suicide warning signs).

Medicines can cause unwanted effects and some require monitoring or a gradual stopping plan. New agitation, marked behavioural change or worsening suicidal thoughts should be reported promptly, particularly around starting or changing an antidepressant. A difficult therapy session should be discussed too; agreed pacing and safety matter (NIMH mental health medications).

Important interactions

Give the clinician or pharmacist the complete list of prescription medicines, non-prescription products, alcohol and recreational substances. Some products act on overlapping systems. NIMH warns that combining serotonergic medicines with certain other drugs or St John’s wort can cause serotonin syndrome. Sedating products can compound impairment. “Natural” does not establish compatibility, and a supplement sold for mood may affect another treatment. Review the actual product and ingredients, rather than assuming a general calming label is enough (NIMH mental health medications).

Who should avoid unsupervised treatment

Children and adolescents, pregnant or breastfeeding patients, older adults with several medicines, and people with complex medical or psychiatric histories need tailored decisions. Anyone with crisis symptoms should avoid substituting self-treatment for urgent assessment. Do not borrow another person’s medicine, copy an adult plan for a child, or use a forum recommendation as an instruction to stop prescribed care. Coexisting conditions may change the risk–benefit balance and the appropriate provider (NIMH mental health medications).

Dosage and how to take

No personal medicine dose, supplement regimen or exposure schedule is provided. Choice, timing, duration, monitoring and stopping depend on the diagnosis, age, other conditions and local instructions. A trial regimen describes what researchers studied, not what every reader should take. Ask the prescriber what benefit to expect, which adverse effects need contact, and how changes will be reviewed. Do not abruptly stop a prescribed medicine without an appropriate clinical plan (NIMH mental health medications).

Animal and in-vitro evidence

Changes in stress hormones, neurotransmitters or behaviour in cells or animals are clues to mechanisms. They cannot establish clinical recovery, functional improvement or safety in a person with this condition. Nor does laboratory activity identify the right human product, formulation or dose. This article excludes animal and cell findings from human efficacy conclusions. Mechanistic plausibility is kept separate from the clinical guidance summarized above.

Funding and source roles

Tier describes financial independence; the letter grade describes credibility for the stated use, not treatment potency. The source mix is concentrated in US and UK institutions, with international sources where indicated. Public funding is checked but does not erase individual or trial-level ties. Medicine, device, therapy, app and supplement providers may earn revenue from care; clinicians and institutions also have professional and service incentives. Those interests do not establish misconduct or a payment to this article.

Frequently asked questions

Is irritability relevant?

It can be. Assessment looks at persistent changes and their effect, not irritability alone.

Can adults’ medicines be copied?

No. Age-specific prescribing, monitoring and psychological care are essential.

Should the young person speak privately?

NICE recommends an opportunity to discuss sensitive assessment issues initially in private, with safeguarding duties explained.

Sources and funding notes

Original source pages were opened for this review, including recommendation text where a guideline is cited. The institution-level funding routes were checked; page-level contributors, guideline declarations and the full financial chain of supporting studies are not all cleared. Public recommendations are therefore reported as guidance, and no drug, device or supplement is assigned an independently verified effect size. Source dates vary and some pages predate the review. This is an educational, selected review rather than an exhaustive systematic search or personal medical advice.

• NHS depression in children and young people — Page last reviewed: 16 May 2023 Next review due: 16 May 2026 Supp
• NICE depression in children and young people — Exact source review date not established
• NIMH depression — Revised 2024
• NIMH psychotherapies — Last Reviewed: February 2024
• NIMH mental health medications — Last Reviewed: December 2023
• NIMH suicide warning signs — Revised 2023
• NCCIH depression — Last Updated: February 2020

Last reviewed: October 4, 2026.